ALPIX — Pixium Vision SA Share News
0.000.00%
Last trade - 00:00- €0.52m
- €5.28m
- €1.96m
Brief: Pixium Vision SA H1 Net Loss EUR 3.0 Million Versus Loss Of EUR 6.4 Million Year Ago
Brief: Pixium Vision Implants 5th PRIMA In Patients With Atrophic Dry-AMD
Brief: Pixium Vision Success Of Its Capital Increase
Brief: Pixium Vision Launches 10.6 Million Euros Capital Increase
Brief: Pixium Vision Reports Cash Position Of 9.8 Million Euros At March 31
Brief: Pixium Vision Announces Successful Activations With Prima In The First Three Patients With Atrophic Dry-Amd
Brief: Pixium Vision FY Operating Loss Widens to 12.7 Million Euros
Brief: Pixium Vision Announces Human Implantation And Activation Of PRIMA Bionic Vision System
Brief: Pixium Vision Gets FDA Approval For Human Clinical Study Of Prima Sub-Retinal Implant
Brief: Pixium Vision 9-month operating revenue at 1.7 million euros
Brief: Pixium Vision establishes an equity line financing with Kepler Cheuvreux
Brief: Pixium Vision gets approval for first-in-human clinical trial of PRIMA
Brief: Pixium Vision announces updates on its epi-retinal Iris II bionic vision system
Brief: Pixium Vision H1 operating loss narrows to 6.1 million euros
Brief: Pixium Vision executes planned drawdown of 2nd tranche of its bond financing agreement
Brief: Pixium Vision in discussion with FDA for a feasibility study with its PRIMA System
Brief: Pixium Vision and research partners report progress in multiple areas with IRIS and PRIMA
Brief: Pixium Vision reports Q1 operating income stable at 0.7 million euros
Brief: Pixium Vision announces planned drawdown of 1st tranche of bond financing agreement